Mutational Portrait of Lung Adenocarcinoma in Brazilian Patients: Past, Present, and Future of Molecular Profiling in the Clinic

Objectives: Approximately 60% of lung adenocarcinomas (LAs) carry mutations that can guide treatment with tyrosine-kinase inhibitors (TKI) and other targeted therapies. Data on activating mutations in EGFR and other tyrosine-kinase receptor (TKR) genes in highly admixed populations, such as that of...

Descripción completa

Detalles Bibliográficos
Autores principales: Freitas, Helano C., Torrezan, Giovana Tardin, da Cunha, Isabela Werneck, Macedo, Mariana Petaccia, Karen de Sá, Vanessa, Corassa, Marcelo, Ferreira, Elisa Napolitano e, Saito, Augusto Obuti, Dal Molin, Graziela Zibetti, Cordeiro de Lima, Vladmir C., Carraro, Dirce Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343968/
https://www.ncbi.nlm.nih.gov/pubmed/32714871
http://dx.doi.org/10.3389/fonc.2020.01068
_version_ 1783555861891776512
author Freitas, Helano C.
Torrezan, Giovana Tardin
da Cunha, Isabela Werneck
Macedo, Mariana Petaccia
Karen de Sá, Vanessa
Corassa, Marcelo
Ferreira, Elisa Napolitano e
Saito, Augusto Obuti
Dal Molin, Graziela Zibetti
Cordeiro de Lima, Vladmir C.
Carraro, Dirce Maria
author_facet Freitas, Helano C.
Torrezan, Giovana Tardin
da Cunha, Isabela Werneck
Macedo, Mariana Petaccia
Karen de Sá, Vanessa
Corassa, Marcelo
Ferreira, Elisa Napolitano e
Saito, Augusto Obuti
Dal Molin, Graziela Zibetti
Cordeiro de Lima, Vladmir C.
Carraro, Dirce Maria
author_sort Freitas, Helano C.
collection PubMed
description Objectives: Approximately 60% of lung adenocarcinomas (LAs) carry mutations that can guide treatment with tyrosine-kinase inhibitors (TKI) and other targeted therapies. Data on activating mutations in EGFR and other tyrosine-kinase receptor (TKR) genes in highly admixed populations, such as that of Brazil, are scarce. In this study, we comprehensively analyzed the actionable alteration profile of LA in Brazilian patients. Materials and Methods: EGFR driver mutation data were collected from a large Brazilian LA cohort covering an 8-year period of molecular testing in a single institution. Tests were performed using three distinct methods, and demographic and histopathological data were analyzed. For a subset of patients, driver mutations in KRAS, NRAS, and BRAF and gene fusions involving TKR genes (before TKI treatment) and EGFR T790M (after TKI treatment) were assessed. Results: EGFR mutations were detected in 25% of 1,316 LAs evaluated, with exon 19 deletions and exon 21 L858R TKI sensitizing mutations representing 72.5% of all mutations. Mutation rates were higher in women and non-smokers (p < 0.001). Next-generation sequencing was very sensitive, with a lower rate of inconclusive results compared with Sanger sequencing and pyrosequencing. EGFR/RAS/BRAF hotspot gene panels were applied in 495 LA cases and detected oncogenic mutations in 51.3% of samples, most frequently in EGFR (22.4%) and KRAS (26.9%). In subgroups of 36 and 35 patients, gene fusions were detected in 11.1% of tumors and EGFR T790M resistance mutations were detected in 59% of plasma samples from patients previously treated with TKI, respectively. Conclusion: This report provides the first comprehensive actionable alteration portrait of LA in Brazil. The high rate of actionable alterations in EGFR and other driver genes in LA reinforces the need to incorporate TKI guided by molecular diagnostics into clinical routines for patients in both public and private healthcare systems.
format Online
Article
Text
id pubmed-7343968
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-73439682020-07-25 Mutational Portrait of Lung Adenocarcinoma in Brazilian Patients: Past, Present, and Future of Molecular Profiling in the Clinic Freitas, Helano C. Torrezan, Giovana Tardin da Cunha, Isabela Werneck Macedo, Mariana Petaccia Karen de Sá, Vanessa Corassa, Marcelo Ferreira, Elisa Napolitano e Saito, Augusto Obuti Dal Molin, Graziela Zibetti Cordeiro de Lima, Vladmir C. Carraro, Dirce Maria Front Oncol Oncology Objectives: Approximately 60% of lung adenocarcinomas (LAs) carry mutations that can guide treatment with tyrosine-kinase inhibitors (TKI) and other targeted therapies. Data on activating mutations in EGFR and other tyrosine-kinase receptor (TKR) genes in highly admixed populations, such as that of Brazil, are scarce. In this study, we comprehensively analyzed the actionable alteration profile of LA in Brazilian patients. Materials and Methods: EGFR driver mutation data were collected from a large Brazilian LA cohort covering an 8-year period of molecular testing in a single institution. Tests were performed using three distinct methods, and demographic and histopathological data were analyzed. For a subset of patients, driver mutations in KRAS, NRAS, and BRAF and gene fusions involving TKR genes (before TKI treatment) and EGFR T790M (after TKI treatment) were assessed. Results: EGFR mutations were detected in 25% of 1,316 LAs evaluated, with exon 19 deletions and exon 21 L858R TKI sensitizing mutations representing 72.5% of all mutations. Mutation rates were higher in women and non-smokers (p < 0.001). Next-generation sequencing was very sensitive, with a lower rate of inconclusive results compared with Sanger sequencing and pyrosequencing. EGFR/RAS/BRAF hotspot gene panels were applied in 495 LA cases and detected oncogenic mutations in 51.3% of samples, most frequently in EGFR (22.4%) and KRAS (26.9%). In subgroups of 36 and 35 patients, gene fusions were detected in 11.1% of tumors and EGFR T790M resistance mutations were detected in 59% of plasma samples from patients previously treated with TKI, respectively. Conclusion: This report provides the first comprehensive actionable alteration portrait of LA in Brazil. The high rate of actionable alterations in EGFR and other driver genes in LA reinforces the need to incorporate TKI guided by molecular diagnostics into clinical routines for patients in both public and private healthcare systems. Frontiers Media S.A. 2020-07-02 /pmc/articles/PMC7343968/ /pubmed/32714871 http://dx.doi.org/10.3389/fonc.2020.01068 Text en Copyright © 2020 Freitas, Torrezan, Cunha, Macedo, Karen de Sá, Corassa, Ferreira, Saito, Dal Molin, Cordeiro de Lima and Carraro. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Freitas, Helano C.
Torrezan, Giovana Tardin
da Cunha, Isabela Werneck
Macedo, Mariana Petaccia
Karen de Sá, Vanessa
Corassa, Marcelo
Ferreira, Elisa Napolitano e
Saito, Augusto Obuti
Dal Molin, Graziela Zibetti
Cordeiro de Lima, Vladmir C.
Carraro, Dirce Maria
Mutational Portrait of Lung Adenocarcinoma in Brazilian Patients: Past, Present, and Future of Molecular Profiling in the Clinic
title Mutational Portrait of Lung Adenocarcinoma in Brazilian Patients: Past, Present, and Future of Molecular Profiling in the Clinic
title_full Mutational Portrait of Lung Adenocarcinoma in Brazilian Patients: Past, Present, and Future of Molecular Profiling in the Clinic
title_fullStr Mutational Portrait of Lung Adenocarcinoma in Brazilian Patients: Past, Present, and Future of Molecular Profiling in the Clinic
title_full_unstemmed Mutational Portrait of Lung Adenocarcinoma in Brazilian Patients: Past, Present, and Future of Molecular Profiling in the Clinic
title_short Mutational Portrait of Lung Adenocarcinoma in Brazilian Patients: Past, Present, and Future of Molecular Profiling in the Clinic
title_sort mutational portrait of lung adenocarcinoma in brazilian patients: past, present, and future of molecular profiling in the clinic
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343968/
https://www.ncbi.nlm.nih.gov/pubmed/32714871
http://dx.doi.org/10.3389/fonc.2020.01068
work_keys_str_mv AT freitashelanoc mutationalportraitoflungadenocarcinomainbrazilianpatientspastpresentandfutureofmolecularprofilingintheclinic
AT torrezangiovanatardin mutationalportraitoflungadenocarcinomainbrazilianpatientspastpresentandfutureofmolecularprofilingintheclinic
AT dacunhaisabelawerneck mutationalportraitoflungadenocarcinomainbrazilianpatientspastpresentandfutureofmolecularprofilingintheclinic
AT macedomarianapetaccia mutationalportraitoflungadenocarcinomainbrazilianpatientspastpresentandfutureofmolecularprofilingintheclinic
AT karendesavanessa mutationalportraitoflungadenocarcinomainbrazilianpatientspastpresentandfutureofmolecularprofilingintheclinic
AT corassamarcelo mutationalportraitoflungadenocarcinomainbrazilianpatientspastpresentandfutureofmolecularprofilingintheclinic
AT ferreiraelisanapolitanoe mutationalportraitoflungadenocarcinomainbrazilianpatientspastpresentandfutureofmolecularprofilingintheclinic
AT saitoaugustoobuti mutationalportraitoflungadenocarcinomainbrazilianpatientspastpresentandfutureofmolecularprofilingintheclinic
AT dalmolingrazielazibetti mutationalportraitoflungadenocarcinomainbrazilianpatientspastpresentandfutureofmolecularprofilingintheclinic
AT cordeirodelimavladmirc mutationalportraitoflungadenocarcinomainbrazilianpatientspastpresentandfutureofmolecularprofilingintheclinic
AT carrarodircemaria mutationalportraitoflungadenocarcinomainbrazilianpatientspastpresentandfutureofmolecularprofilingintheclinic